Selected publications
-
Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study.
Journal of Clinical Oncology.
2018
Academic Article
GET IT
Times cited: 69 -
Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma.
Journal of Pathology.
2018
Academic Article
GET IT
Times cited: 4 -
Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer.
Journal of Clinical Oncology.
2016
Review
GET IT
Times cited: 96 -
Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3.
Journal of Clinical Oncology.
2016
Conference Paper
GET IT
Times cited: 349 -
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.
Annals of Oncology.
2016
Academic Article
GET IT
Times cited: 70 -
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Expanded access in North America.
Prostate.
2015
Academic Article
GET IT
Times cited: 12 -
Metastatic large-cell neuroendocrine prostate carcinoma: Successful treatment with androgen deprivation therapy.
Clinical Genitourinary Cancer.
2014
Academic Article
GET IT
Times cited: 9 -
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: Exploratory analysis of data from the COU-AA-301 randomised trial.
The Lancet Oncology.
2012
Academic Article
GET IT
Times cited: 201 -
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
The Lancet Oncology.
2012
Academic Article
GET IT
Times cited: 790 -
Increased survival with enzalutamide in prostate cancer after chemotherapy.
New England Journal of Medicine.
2012
Academic Article
GET IT
Times cited: 2442 -
Abiraterone and increased survival in metastatic prostate cancer.
New England Journal of Medicine.
2011
Academic Article
GET IT
Times cited: 2642 -
Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets.
European Urology.
2009
Review
GET IT
Times cited: 119 -
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.
Journal of the National Cancer Institute.
2005
Academic Article
GET IT
Times cited: 237